Top drug from Sanofi’s $1.5B Kymab buy­out aces PhI­Ib in eczema

Two years ago, Sanofi CEO Paul Hud­son made a bet on OX40L as an an­ti-in­flam­ma­to­ry tar­get when he bought out Kymab for $1.5 bil­lion.

Now, the com­pa­ny says Phase IIb da­ta have borne out the po­ten­tial of the top can­di­date from the deal, paving the way for a “larg­er” Phase III de­vel­op­ment pro­gram and back­ing up Sanofi’s am­bi­tions to build a lead­ing im­munol­o­gy fran­chise.

In a re­cent in­ter­view with End­points News, Hud­son spot­light­ed the up­com­ing read­out of the drug, am­lite­limab, as some of the most im­por­tant da­ta com­ing out of Sanofi’s pipeline. The key ques­tion, as he put it: “Will it be Dupix­ent but bet­ter, or will it be Dupix­ent but with a longer in­ter­val?”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER